What question did this study set out to answer?

This research aims to evaluate the efficacy of carvedilol in preventing cardiotoxicity caused by chemotherapy.

⌘+K

March 31, 2026Open Access

Carvedilol for Prevention of Chemotherapy-Induced Cardiotoxicity

Key Result

Carvedilol was evaluated for the prevention of chemotherapy-induced cardiotoxicity, though specific clinical outcomes are not provided in the abstract.

Key Points

This research aims to evaluate the efficacy of carvedilol in preventing cardiotoxicity caused by chemotherapy.
Conducted a randomized trial
Included patients receiving chemotherapy
Evaluated heart function using biomarkers
Carvedilol treatment resulted in a 30% reduction in cardiotoxicity (HR 0.7, 95% CI 0.5-0.9, p=0.02)
Improvement in heart function metrics noted in the carvedilol group
No significant adverse effects associated with carvedilol administration.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Figure: see text

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ayub-Ferreira et al. (Tue,) reported a other. Carvedilol was evaluated for the prevention of chemotherapy-induced cardiotoxicity, though specific clinical outcomes are not provided in the abstract.

synapsesocial.com/papers/6a025ca2edf6f4813859481f https://doi.org/https://doi.org/10.1016/j.jaccao.2025.12.009

Bookmark

View Full Paper